Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Tibet Rhodiola Pharmaceutical Holding Co FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Tibet Rhodiola Pharmaceutical Holding Co FCF Yield % Related Terms
Tibet Rhodiola Pharmaceutical Holding Co FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tibet Rhodiola Pharmaceutical Holding Co FCF Yield % Chart
Tibet Rhodiola Pharmaceutical Holding Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Rhodiola Pharmaceutical Holding Co's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tibet Rhodiola Pharmaceutical Holding Co FCF Yield % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) has a FCF Yield % of 8.40 as of Jul. 14, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. This is 55% above median its historical median of 5.42. According to the industry distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #145 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 14.4%.
Is Tibet Rhodiola Pharmaceutical Holding Co's FCF Yield % too high?
Tibet Rhodiola Pharmaceutical Holding Co's current FCF Yield % of 8.40 is 55% above median its 10-year median of 5.42. The Drug Manufacturers industry median FCF Yield % is 0.67. Tibet Rhodiola Pharmaceutical Holding Co's value of 8.40 is 1153.7% above this industry median. Based on the distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #145 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tibet Rhodiola Pharmaceutical Holding Co has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tibet Rhodiola Pharmaceutical Holding Co's FCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #145 out of 1006 companies for FCF Yield %. This places Tibet Rhodiola Pharmaceutical Holding Co in the top 14% of its industry — outperforming the majority of peers. The industry median FCF Yield % is 0.67. Tibet Rhodiola Pharmaceutical Holding Co's value of 8.40 is 1153.7% above this benchmark. While the company's 10-year median is 5.42 vs. the industry median of 0.67, Tibet Rhodiola Pharmaceutical Holding Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tibet Rhodiola Pharmaceutical Holding Co's current FCF Yield % of 8.40 is 1153.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tibet Rhodiola Pharmaceutical Holding Co's current FCF Yield % is 8.40, which is 55% above median its own 10-year median of 5.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tibet Rhodiola Pharmaceutical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) is currently considered Fairly Valued. The stock's GF Value™ is ¥40.53, compared to a current price of ¥39.30 — trading 3% below its estimated fair value. The current FCF Yield % is 8.40, which is 55% above median its 10-year median of 5.42 and 1153.7% above the Drug Manufacturers industry median of 0.67. Tibet Rhodiola Pharmaceutical Holding Co's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211), the current FCF Yield % is 8.40 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Overvalued in 2026?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co stock appears to be undervalued.
The current stock price of ¥39.30 is trading 3% below its estimated GF Value™ of ¥40.53.
GuruFocus considers Tibet Rhodiola Pharmaceutical Holding Co to be Fairly Valued.
Key valuation signals for SHSE:600211:
FCF Yield %: 8.40 (55% above median its 10-year median of 5.42)
GF Value™: ¥40.53 vs. price of ¥39.30 (3% below fair value)
Industry Position: 1153.7% above the Drug Manufacturers median (#145 of 1006)
No single metric tells the full story. See the SHSE:600211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tibet Rhodiola Pharmaceutical Holding Co Business Description
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
94GF Score
Get the complete analysis for SHSE:600211
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600211 has been successfully added to your 
